Ingram Micro Cloud Adds TeamViewer to Cloud Marketplace to Empower the Remote Workforce
13.4.2020 16:00:00 EEST | Business Wire | Press release
Ingram Micro Cloud today announced the addition of leading secure remote connectivity solutions from TeamViewer to the Ingram Micro Cloud Marketplace as part of a global cloud distribution agreement.
With remote work on the rise, security, collaboration and support challenges abound for today’s distributed workforce. According to Global Workplace Analytics, since 2005, there has been a 173% increase in employees working from home, with 43% of today’s workforce working remotely with some frequency.
TeamViewer’s products will initially be available in 15 countries, including Netherlands, Belgium, France, Spain, United Kingdom, Australia, New Zealand and several Nordic countries. Shortly thereafter, the products will be available in the United States, Brazil and Chile.
Ingram Micro Cloud will distribute the following TeamViewer products:
- Secure Remote Access and Support: Allows system administrators to access remote servers, securely from anywhere, without needing VPN. Business users can also use TeamViewer to remotely access their work computers from off-site locations.
- Centralized Remote Monitoring and Management: Provides the ability to manage, monitor, track, patch, backup, and protect computers, devices, and software—all from a single platform.
- TeamViewer Pilot: Provides remote assistance using augmented reality technology, either for repair or maintenance of a device, or machine, and also enables quick collaboration to fix issues or train colleagues from any location.
“We are delighted to announce this relationship with TeamViewer to accelerate their growth in the channel,” said Ashwin Viswanath, director of Ingram Micro Cloud’s global cloud portfolio strategy. “Leveraging our CloudBlue Connect product catalog, together with our CloudBlue Commerce platform, we are uniquely positioned to magnify the discoverability and distribution of TeamViewer’s offerings across our reseller base.”
“At TeamViewer, we are always striving to reach out to more people across all geographies and walks of life with our remote solutions. We need reliable partners in order to do that,” says Rajesh Nakarajan, sales director at TeamViewer. “Teaming with Ingram Micro Cloud fulfills these needs and will increase our outreach and strengthen our distribution network.”
About Ingram Micro Cloud
Ingram Micro Cloud brings together innovators and problems solvers to help the world accomplish more. It facilitates and manages the cloud’s complex digital value chain—all powered by CloudBlue technology. Ingram Micro Cloud operates in 64 countries with over 55,000 reseller partners, and its Cloud Marketplace serves 6.5 million seats, offering more than 120 cloud solutions. With unmatched global reach, easy access to automated go-to-market and integration tools, deep technical expertise, and a curated selection of scalable SaaS and IaaS solutions, Ingram Micro Cloud helps vendors, resellers and managed service providers by offering More as a Service. Detailed information is available at www.IngramMicroCloud.com.
About TeamViewer
As a leading global provider of remote connectivity solutions, TeamViewer empowers users to connect anything, anywhere, anytime. The company offers secure remote access, support, control and collaboration capabilities for online endpoints of any kind. By innovating with cutting-edge yet easy-to-deploy Augmented Reality (AR) and Internet of Things (IoT) implementations, the company enables businesses of all sizes to tap into their full digital potential. TeamViewer has been activated on more than 2 billion devices; more than 45 million devices are online at any time. Founded in 2005 in Goppingen, Germany, the company employs about 800 people in offices across Europe, the United States and Asia Pacific. For more information, go to www.teamviewer.com and follow us on social media.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200413005087/en/
Contact information
Global Media Contact:
David Yang
CloudBlue and Ingram Micro Cloud
714-382-3357
david.yang@ingrammicro.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom